You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

BMS’ Opdivo plus Yervoy misses the mark in high-risk melanoma

Bristol Myers Squibb has revealed some underwhelming results for its immunotherapy combination treatment Opdivo plus Yervoy in resected high-risk melanoma patients.